Non-Cyclic Rozanolixizumab Administration in Complex Generalized Myasthenia Gravis - PubMed
3 hours ago
- #Myasthenia Gravis
- #Rozanolixizumab
- #FcRn Inhibition
- Rozanolixizumab, an FcRn inhibitor, used for refractory generalized myasthenia gravis (gMG), may have 'wearing-off' effects with cyclic regimens.
- Study evaluated non-cyclic rozanolixizumab administration (weekly or fortnightly) in eight complex gMG patients, defined by refractoriness or high activity.
- Primary outcome: ≥2-point improvement in MG-ADL score at 3 months; mean baseline score of 10.8 improved to 4.1, with sustained benefits up to 12 months.
- Hospitalization days reduced from 15.8/month pre-treatment to zero by 6-12 months, and corticosteroid use tapered significantly.
- Serum IgG levels declined by nearly 50% and stabilized; only one discontinuation due to gastrointestinal symptoms, with no serious adverse events.
- Non-cyclic dosing may prevent cyclical relapses, offering steroid-sparing therapy; larger studies needed for long-term safety and efficacy confirmation.